Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|December 13, 2021
Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven TumorsAdina Gerson-Gurwitz, Nathan P Young, Vikas K Goel, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery and development of potent and selective inhibitors of histone methyltransferase g9aRamzi F Sweis, Marina Pliushchev, Peter J Brown, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2Ramzi F Sweis, Zhi Wang, Mikkel Algire, et al.
Plos One|July 7, 2015
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of LeukemiaWilliam N Pappano, Jun Guo, Yupeng He, et al.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED bindingMichael L Curtin, Marina A Pliushchev, Huan-Qiu Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2025
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Ezra Y Rosen, Malvika Sharma, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerJacob A Boyer, Malvika Sharma, Madeline A Dorso, et al.
Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.
Pageof 4